Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7339090

COc1ccc2ccc(C(=N)N)cc2c1Oc1ncccn1.O=C(O)C(F)(F)F

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PLAU P00749 12/20 0.57
F2 P00734 7/20 0.42
F3 P13726 4/20 0.42
PRSS1 P07477 7/20 0.40
PLG P00747 4/20 0.40
KLK1 P06870 4/20 0.40
PLAT P00750 3/20 0.40
F10 P00742 1/20 0.40
F7 P08709 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7337301 0.85 PLAU (0.64) PLAUF2PRSS1PLGKLK1
Trifluoroacetic Acid SCHEMBL7339921 0.84 PLAU (0.57) PLAUF2F3PRSS1PLG
Trifluoroacetic Acid SCHEMBL7333225 0.82 PLAU (0.73) PLAUF2PRSS1PLGKLK1
Trifluoroacetic Acid SCHEMBL7345791 0.82 PLAU (0.84) PLAUF2PRSS1PLGKLK1
Trifluoroacetic Acid SCHEMBL7342930 0.80 PLAU (0.61) PLAUF2PRSS1PLGKLK1
Trifluoroacetic Acid SCHEMBL7343140 0.80 PLAU (0.61) PLAUF2PRSS1PLGKLK1
Trifluoroacetic Acid SCHEMBL7456773 0.80 PLAU (0.70) PLAUF2PRSS1PLGKLK1
Trifluoroacetic Acid SCHEMBL7344757 0.79 PLAU (0.62) PLAUF2PRSS1PLGKLK1
Trifluoroacetic Acid SCHEMBL7337885 0.79 PLAU (0.55) PLAUF2PRSS1PLGKLK1
Trifluoroacetic Acid SCHEMBL7592047 0.79 PLAU (0.56) PLAUF2PRSS1PLGKLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP claimed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885F2 38/4885F3 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.